Drug intelligence / Profile preview

MBTC-ND-EVs

Development stage: Preclinical
Lead developer: Stemmedicare
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

MBTC-ND-EVs is an extracellular vesicle (EV)-based therapeutic candidate being developed by Stemmedicare for the treatment of neurodegenerative diseases, specifically Alzheimer's disease and Parkinson's disease. The drug utilizes Stemmedicare's proprietary EV technology to deliver therapeutic signals or cargo intended to address the underlying pathology of these conditions. As of the current pipeline status, the program is in the efficacy verification and candidate selection stage, which is categorized as preclinical development. The specific biological targets and route of administration have not been publicly disclosed.

Other names: MBTC-ND-EVs (Neurodegenerative Diseases)

Beyond the preview

Go deeper on MBTC-ND-EVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBTC-ND-EVs.

Explore the full profile